-
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes.
Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for healthy eating. In...
IN THE SPOTLIGHT
-
Small Cell SMASHERS Fireside Chat with Dr. Triparna Sen
Join us for a Facebook Live on Friday, November 1, as Triparna Sen, PhD, Icahn School of Medicine at Mount Sinai, discusses the biology and the role of biomarkers in small cell... -
Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This is the second blog in our series of updates from the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical... -
Small Cell SMASHERS Fireside Chat with Dr. Christine Lovly - Video
Missed the Facebook Live? Watch the video! On Tuesday, October 8, Christine Lovly, MD, PhD, discussed the importance of clinical trials and the role of translational research in... -
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug... -
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
SCLC Virtual Meetup
SCLC patients/survivors - Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. Register in advance for this... -
Small Cell Lung Cancer 101
Join small cell lung cancer expert Lauren Byers, MD, as she covers the key things patients need to know about SCLC in 30 minutes. Dr. Byers is a professor in the Department of...
Tarlatamab in Combination Therapy: Future Potential for SCLC
Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer
Fox Chase Cancer Center Researchers Find Gene That Triggers Immune Response in Treatment-Resistant Small-Cell Lung Cancer
Adverse Event Management: CRS and ICANS with Tarlatamab
Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This is the second blog in our series of updates from the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference, held in Barcelona from September 13-17. This update focuses on small cell lung cancer (SCLC), which is seen in 15% of people diagnosed with lung cancer. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Early-Stage and Locally…
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Screening and Early Detection of Lung Cancer: Highlights from WCLC and ESMO 2024
Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Small Cell Lung Cancer…
Small Cell SMASHERS Fireside Chat with Dr. Christine Lovly - Video
Small Cell SMASHERS Fireside Chat with Dr. Christine Lovly - Video
Missed the Facebook Live? Watch the video!On Tuesday, October 8, Christine Lovly, MD, PhD, discussed the importance of clinical trials and the role of translational research in small cell lung cancer (SCLC). The discussion was moderated by Misty Shields, MD, IU Health, and LUNGevity’s Amy C. Moore, PhD and VP of Global Engagement and Research Partnerships. This monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.
Small Cell SMASHERS Fireside Chat with Dr. Triparna Sen
Small Cell SMASHERS Fireside Chat with Dr. Triparna Sen
Join us for a Facebook Live on Friday, November 1, as Triparna Sen, PhD, Icahn School of Medicine at Mount Sinai, discusses the biology and the role of biomarkers in small cell lung cancer. Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this new monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.
Eating Healthy on the Mediterranean Diet
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for healthy eating. In addition to the studied health benefits, Lori highlights the unique foods and flavors that make this diet special and provides simple, practical tips on how to incorporate them into your daily meals. In the video below, Lori offers a firsthand look at how easy and enjoyable it can be…
Immunotherapy Instills Renewed Promise in SCLC
Small Cell SMASHERS Fireside Chat - September 2024
Small Cell SMASHERS Fireside Chat - September 2024
LUNGevity and the Small Cell SMASHERS hosted their first fireside chat on September 20, 2024, with Anne Chiang, MD, PhD, associate professor of medicine and thoracic medical oncologist at Yale University.Leading the discussion with Dr. Chiang were Misty Shields, MD, PhD, thoracic oncologist at Indiana University, and Ann Steagall, RN, BSN, LUNGevity's senior vice president of patient services and healthcare delivery.
Durvalumab Consolidation Extends Survival in LS-SCLC, ADRIATIC Findings Show
Ponsegromab Could Offer Further Treatment for Cancer Cachexia
Novel Agent Effective for Cancer Wasting Disorder
FDA Grants Breakthrough Status To GSKs Lung Cancer Drug
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug Development? Part 2: How We Define Success for a Clinical Trial The United States federal government aims to regulate prescription drugs to ensure people are receiving medication that’s safe and effective. Every prescribed drug in the U.S. has gone through a rigorous testing process that can…
How We Define Success for a Clinical Trial
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The…
Imfinzi Granted Priority Review and Breakthrough Therapy Designation for Limited-Stage Small Cell Lung Cancer in the US
Imfinzi Granted Priority Review and Breakthrough Therapy Designation for Limited-Stage Small Cell Lung Cancer in the US
Durvalumab Gets Priority Review for Limited-Stage Small Cell Lung Cancer
Understanding Clinical Trials: Why Are They Important for Drug Development?
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes.This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.According to the National Cancer Institute, a clinical trial is a type of research study that tests how well new medical approaches (such as screening tests, prevention…
New NCCN Guidelines for Patients
New NCCN Guidelines for Patients
The National Comprehensive Cancer Network (NCCN) is an alliance of leading cancer centers across the United States working together to improve cancer care. NCCN develops evidence-based cancer care recommendations used by healthcare providers worldwide, and they release a companion version of the guidelines specifically for people with cancer and their caregivers.The newly updated and published guidelines for patients with small cell lung cancer can be viewed, downloaded, and printed here. Learn…
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for…
How Can Patients and Researchers Design Clinical Trials Together?
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…
2024 ASCO: Highlights of Lung Cancer Research
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutesThousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. The theme for this year’s conference, “The Art and Science of Cancer Care: From Comfort to Cure,” highlighted the importance of using both our creativity and our scientific…
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning. To help us better understand the needs of this growing…
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. You can watch the full 40-minute conversation with Kathy or use the timestamps below to learn more about the topics and advice…
New Treatment Approved for Patients with Extensive Stage SCLC
New Treatment Approved for Patients with Extensive Stage SCLC
On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung cancer (SCLC). This targeted immunotherapy, the first of its kind, is based on new technology. Tarlatamab is a bispecific T-cell engager (BiTE)—a drug with two arms that simultaneously binds to a T cell (a part of the immune system) and a tumor cell. This allows the T cell to come close enough to the tumor cell…
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutesIntegrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of…
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutesIt’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of you who are new to this meeting, it is the largest gathering of laboratory scientists and clinicians in the world—coming together to discuss how to take science from the bench (laboratory) to patients and communities. This year’s meeting was held in sunny San Diego and brought together more than 23,000 attendees. Below…
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her…
Despite Challenges, Treatment Advances for SCLC
Despite Challenges, Treatment Advances for SCLC
This March, LUNGevity Foundation partnered with CURE for their ”Speaking Out” video series, featuring Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation. This interview with Dr. Moore delves into recent breakthroughs in the treatment of small cell lung cancer (SCLC). Dr. Moore discusses significant advances highlighted in clinical trials, such as the IMpower133 and CASPIAN studies, demonstrating the efficacy of combining immunotherapy with…